1. Home
  2. ANET vs NVO Comparison

ANET vs NVO Comparison

Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arista Networks Inc.

ANET

Arista Networks Inc.

HOLD

Current Price

$174.42

Market Cap

173.1B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$44.49

Market Cap

166.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANET
NVO
Founded
2004
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.1B
166.1B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ANET
NVO
Price
$174.42
$44.49
Analyst Decision
Strong Buy
Hold
Analyst Count
17
11
Target Price
$175.18
$51.00
AVG Volume (30 Days)
6.5M
14.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
3.19%
EPS Growth
23.32
N/A
EPS
2.75
N/A
Revenue
$9,005,700,000.00
N/A
Revenue This Year
$29.10
N/A
Revenue Next Year
$21.80
$3.70
P/E Ratio
$62.98
$13.60
Revenue Growth
28.60
N/A
52 Week Low
$82.80
$35.12
52 Week High
$179.80
$81.44

Technical Indicators

Market Signals
Indicator
ANET
NVO
Relative Strength Index (RSI) 66.07 69.50
Support Level $119.88 $43.16
Resistance Level $179.80 $50.30
Average True Range (ATR) 6.15 1.03
MACD 0.11 0.59
Stochastic Oscillator 81.90 98.40

Price Performance

Historical Comparison
ANET
NVO

About ANET Arista Networks Inc.

Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: